Clinical trials
Lung Cancer Screening clinical trials
Below are recruiting lung cancer screening clinical trials, each written for real people, not researchers. We’re tracking 689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT07367529RecruitingPhase 1/Phase 2
Study of TQB6411 for people with lung cancer
This trial tests a new drug called TQB6411 for people with lung cancer. It aims to see if the drug is safe and effective, and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–75 - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06970639RecruitingPhase 3
Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Guangdong, GuangzhouAges 18 years+ - NCT07264816RecruitingPhase 2
Study of BL-M07D1 and Pembrolizumab for HER2+ Lung Cancer
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
Wuhan, HubeiAges 18–75 - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06371482RecruitingPhase 2
Durvalumab plus chemoradiation for limited-stage small cell lung cancer
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Shijiazhuang, HebeiAges 18–75 - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT07560111RecruitingPhase 2
GC101 cell therapy for advanced lung cancer
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
ShanghaiAges 18–70 - NCT07402343RecruitingPhase 2
Tarlatamab for small cell lung cancer brain metastases
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
AmsterdamAges 18 years+ - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT07459634RecruitingPhase 2
Lurbinectedin with durvalumab for extensive-stage small cell lung cancer
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
Los Angeles, CaliforniaAges 18 years+ - NCT03803787RecruitingPhase 2
Inhaled steroid to prevent lung inflammation during cancer treatment
This trial tests whether breathing in steroid medicine before and during radiation can lower how often and how badly “radiation lung inflammation” (radiation pneumonitis) happens in people with lung cancer. If you qualify, it may help protect your lungs while you receive radiation with chemotherapy or targeted therapy.
Mexico CityAges 18–75 - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04591002RecruitingPhase 2
Osimertinib after lung cancer surgery to slow new lung spots
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
Seoul, KangnamguAges 30–75 - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04875585RecruitingPhase 2
Neoadjuvant and post-surgery immunotherapy for operable lung cancer
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Innsbruck, TyrolAges 18 years+
Hear when a new Lung Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer screening?
- Yes. Clin2 currently lists 689 recruiting lung cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.